Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in the United States. These conditions are caused by a combination of factors, including genetic, behavioral, environmental, and medical influences. Obesity is a major risk factor for cardiovascular and metabolic diseases. A comprehensive treatment plan for individuals with obesity must recognize the chronic nature of the condition and offer strategies for weight reduction and long-term cardiometabolic benefits. Over the past several decades, multiple therapeutic options have been implemented to address weight loss, appetite regulation, and caloric expenditure, with the goal of reducing the burden of obesity and improving cardiovascular outcomes. Pharmacological treatment of obesity has focused primarily on the central regulation of appetite and food intake behavior. The introduction of incretin agonists for obesity treatment has ushered in a new era of cardiometabolic health, with a multitargeted mechanism that achieves weight loss, glycemic control, decreased cardiovascular mortality, and other metabolic benefits. This review explores the current pharmacological options and the future of obesity treatment.
21 October 2019 in Baylor University Medical Center Proceedings
Bariatric procedures for weight loss have increased in the past few decades. Levothyroxine malabsorption has been reported following gastric bypass; however, few studies have addressed this issue after gastric sleeve procedures. Levothyroxine dosing is usually weight based and administered at approximately 1.6 μg/kg body weight. Absorption occurs mainly in the jejunum and upper ileum, which can be altered by gastric pH, other drugs, food, and other factors. We present a 35-year-old woman with longstanding iatrogenic hypothyroidism treated with thyroxine, whose thyroid-stimulating hormone level rose following a gastric sleeve procedure despite taking levothyroxine daily.
1 November 2019 in Baylor University Medical Center Proceedings
Vitamin D deficiency is common in patients with primary hyperparathyroidism. We present a case of primary hyperparathyroidism with a positive parathyroid scan and history of nephrolithiasis. The patient had normal albumin and renal function but was vitamin D deficient. After treatment with vitamin D for 13 months, her parathyroid hormone values declined in parallel with the elevation in vitamin D. Although her total calcium normalized, her ionized calcium remained elevated throughout treatment. We believe vitamin D deficiency should be carefully monitored in primary hyperparathyroidism.
The global rise in obesity and cardiometabolic disease represents a major public health concern and contributes significantly to cardiovascular morbidity and mortality. Contemporary Western dietary patterns and excess adiposity are strongly associated with atherosclerotic cardiovascular disease. Although pharmacologic therapies have expanded, lifestyle interventions remain the cornerstone of prevention and management. However, identifying sustainable and effective dietary approaches continues to be challenging given the wide range of available nutrition regimens. Intermittent fasting (IF) has emerged as a promising strategy for weight reduction and metabolic improvement. In this article, we review the physiological effects of IF, including metabolic switching, ketosis, and improvements in insulin sensitivity and inflammatory regulation. We also evaluate clinical evidence regarding the impact on cardiovascular risk, as well as its safety and tolerability. We examine the hormonal responses to IF based on sex. While early studies raised concerns regarding potential reproductive and endocrine disturbances, recent data suggest beneficial effects in both males and females. IF may modestly reduce testosterone in men without impairing muscle mass or strength and may improve metabolic and reproductive outcomes in women, particularly those with hyperandrogenic conditions such as polycystic ovarian syndrome, with favorable effects also observed in postmenopausal women, especially when combined with physical activity.
20 January 2026 in The Journal of Clinical Endocrinology & Metabolism
Context: Severe thyrotoxicosis and thyroid storm have a high morbidity and mortality risk and are commonly managed with antithyroid drugs. In some patients, a combination therapy with medications and thyroidectomy as definite treatment are required. Therapeutic Plasma Exchange (TPE) can be used as a temporizing measure to achieve thyroid hormone normalization and to prevent perioperative complications before surgery. Objective: We describe 6 cases of severe thyrotoxicosis and/or thyroid storm who underwent TPE as a bridge to thyroidectomy and present the clinical characteristics and outcomes. We aim to propose a preoperative thyroid hormone target. Methods: We collected data of 6 patients who were diagnosed with severe thyrotoxicosis or thyroid storm between April 2023 and April 2024 and that were treated with TPE due to high mortality risk or refractoriness to medical treatment. Data collected included the baseline clinical characteristics, laboratory data, clinical progress, and outcomes. Thyroid hormone levels at diagnosis, before initiation of TPE, and before thyroidectomy were compared using statistical analysis. Results: Four of 6 patients underwent thyroidectomy, and 2 patients died due to multiorgan dysfunction. The mean free T4 (fT4) level at diagnosis was 4.8 ng/dL (reference range, 0.8-1.8 ng/dL), 5.4 ng/dL pre-TPE, and 2.6 ng/dL prethyroidectomy, resulting in a mean difference of 2.8 ng/dL (51.7%) reduction (95% CI, 1.1-4.5; P = .01). The number of TPE treatments to reach a preoperative fT4 level of 2.5 ng/dL was 5.5 treatments (P = .03). Conclusion: These results reflect efficacy of TPE as a bridge to thyroidectomy and suggest that a preoperative fT4 goal of 2.5 to 3.3 can be considered in patients with severe thyrotoxicosis and thyroid storm that are refractory to medical treatment.